从基因表达谱解读一项「阴性」ICU试验
该研究对一项在三级学术机构混合内外科ICU开展的随机对照试验所收集的转录组与临床数据进行生物信息学分析,研究对象为预计需要有创机械通气超过48小时的成人重症患者,干预为乳铁蛋白或安慰剂经肠内及口腔拭子给药最长28天。分析未发现组间转录组特征存在重大失衡,入组时无监督分析未揭示患者间存在明显聚类,早期与后期时间点之间基因表达存在显著差异,乳铁蛋白组显示与已知乳铁蛋白相关免疫通路有关的基因表达变化。作者认为转录组数据是临床数据的有用补充,阴性结果的原因较不可能与药物生物学疗效相关,而可能与临床结局敏感性不足有关,并认为在更大型研究中转录组学可能有助于预测治疗反应。
要点
- 入组时两组转录组特征无重大失衡,无监督分析未发现患者存在明显聚类。
- 早期与后期时间点之间基因表达存在显著差异。
- 乳铁蛋白组出现与已知乳铁蛋白相关免疫通路有关的基因表达变化。
- 作者认为阴性结果较不可能源于药物生物学疗效不足,而可能与临床结局敏感性不足有关。
- 作者认为在更大型研究中转录组学可能有助于预测治疗反应。
适用人群与场景
- 三级学术机构混合内外科ICU的成人重症患者,预计需要有创机械通气超过48小时。
处置流程与药物剂量
- 乳铁蛋白或安慰剂经肠内及口腔拭子给药,最长28天。
研究设计与关键结果
- 研究设计为对一项随机对照试验过程中收集的转录组与临床数据进行生物信息学分析,场景为三级学术混合内外科ICU。
- 干预为乳铁蛋白或安慰剂经肠内及口腔拭子给药最长28天。
- 两组间转录组特征无重大失衡。
- 入组时无监督分析未揭示患者间存在明显聚类。
- 早期与后期时间点之间基因表达存在显著差异。
- 乳铁蛋白组显示与已知乳铁蛋白相关免疫通路有关的基因表达变化。
证据类型、等级与局限
- 证据类型:对随机对照试验转录组与临床数据的生物信息学分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为转录组数据是临床数据的有用补充。
- 作者认为该阴性结果的原因较不可能与研究药物生物学疗效相关,而可能与临床结局敏感性不足有关。
- 作者认为在更大型研究中转录组学可能有助于预测治疗反应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Randomized controlled trials in the ICU often fail to show differences in endpoints between groups. We sought to explore reasons for this at a molecular level by analyzing transcriptomic data from a recent negative trial. Our objectives were to determine if randomization successfully balanced transcriptomic features between groups, to assess transcriptomic heterogeneity among the study subjects included, and to determine if the study drug had any effect at the gene expression level.
DESIGN: Bioinformatics analysis of transcriptomic and clinical data collected in the course of a randomized controlled trial.
SETTING: Tertiary academic mixed medical-surgical ICU.
PATIENTS: Adult, critically ill patients expected to require invasive mechanical ventilation more than 48 hours.
INTERVENTIONS: Lactoferrin or placebo delivered enterally and via an oral swab for up to 28 days.
MEASUREMENTS AND MAIN RESULTS: We found no major imbalances in transcriptomic features between groups. Unsupervised analysis did not reveal distinct clusters among patients at the time of enrollment. There were marked differences in gene expression between early and later time points. Patients in the lactoferrin group showed changes in the expression of genes associated with immune pathways known to be associated with lactoferrin.
CONCLUSIONS: In this clinical trial, transcriptomic data provided a useful complement to clinical data, suggesting that the reasons for the negative result were less likely related to the biological efficacy of the study drug, and may instead have been related to poor sensitivity of the clinical outcomes. In larger studies, transcriptomics may also prove useful in predicting response to treatment.
参考来源
- Hoekstra M, Maslove DM, Veldhoen RA, et al. Insights Into a "Negative" ICU Trial Derived From Gene Expression Profiling. Crit Care Med. 2019. PMID: 30817329. doi:10.1097/CCM.0000000000003693
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。